|
|
Volumn 67, Issue 5, 2010, Pages 335-
|
|
Dalfampridine approved for MS
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMPYRA;
DALFAMPRIDINE;
PLACEBO;
POTASSIUM CHANNEL BLOCKING AGENT;
UNCLASSIFIED DRUG;
CLINICAL TRIAL;
DISEASE SEVERITY;
DIZZINESS;
DRUG APPROVAL;
DRUG INDUCED HEADACHE;
DRUG LABELING;
DRUG MARKETING;
FOOD AND DRUG ADMINISTRATION;
GASTROINTESTINAL SYMPTOM;
HUMAN;
INSOMNIA;
KIDNEY DYSFUNCTION;
MULTIPLE SCLEROSIS;
NONHUMAN;
NOTE;
PRIORITY JOURNAL;
QRS COMPLEX;
QT INTERVAL;
RECOMMENDED DRUG DOSE;
ROOM TEMPERATURE;
SEIZURE;
SORE THROAT;
TABLET;
TREATMENT CONTRAINDICATION;
TREATMENT OUTCOME;
URINARY TRACT INFECTION;
WEAKNESS;
|
|
EID: 77949634115
PISSN: 10792082
EISSN: None
Source Type: Journal
DOI: 10.2146/news100015 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|
